Hormonal contraceptives can affect mood, and for some people they may worsen pre-existing mood disorders, but the evidence is mixed and individual. Large observational studies have reported associations between hormonal contraceptive use and increased antidepressant prescriptions or mood diagnoses in certain groups, while clinical recommendations emphasize individualized assessment and monitoring rather than blanket avoidance.
Evidence from population studies and guidelines
A notable nationwide cohort analysis by Cecilia W. Skovlund University of Copenhagen evaluated links between hormonal contraception and subsequent mood-related care; it identified associations that were stronger in adolescents and in some users of combined and progestin-only preparations. Observational work like this is important but has limitations: it cannot prove causation and may reflect selection or detection biases. Professional bodies such as the Committee on Adolescent Health Care American College of Obstetricians and Gynecologists advise clinicians to take a reproductive and psychiatric history, counsel about possible mood effects, and arrange follow-up rather than assuming universal harm.
Biological mechanisms and clinical consequences
Biologically, sex steroids modulate neurotransmitter systems including serotonin, gamma-aminobutyric acid, and neurosteroid pathways, offering plausible mechanisms by which estrogen and progestins may influence mood. Individual responses depend on the specific hormonal formulation, dose, route of administration, and a person’s neurobiology. In practice, worsening mood can lead to treatment discontinuation, destabilization of an already-managed psychiatric condition, and, in rare cases among vulnerable adolescents, increased risk of self-harm behaviors if not promptly addressed.
Clinicians should apply shared decision-making, weighing contraceptive benefits against potential mood risks for each person. For those with a history of depressive or anxiety disorders, consider closer monitoring, early psychiatric collaboration, or trials of different formulations; some patients may do better on combined regimens, others on non-hormonal methods. Cultural and territorial factors—stigma around mental health, differential availability of contraceptive options, and disparities in integrated care—affect how risks are discussed and managed in real-world settings. Careful history-taking, clear communication about signs of worsening mood, and timely follow-up remain the most evidence-aligned strategies to minimize harm while preserving reproductive autonomy.